Histologic Assessment of Lichenoid Dermatitis Observed in Patients with Advanced Malignancies on Antiprogramed Cell Death-1 (anti-PD-1) Therapy with or Without Ipilimumab

American Journal of Dermatopathology

Volumn 39, Issue 1, 2017, Pages 23-27

  Chou, Shaun ^a   Hwang, Shelley Ji Eun ^a,b   Carlos, Giuliana ^a,b   Wakade, Deepal ^a,b   Fernandez Penas, Pablo ^a,b  

^a WESTMEAD HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

adverse drug reaction; CTLA 4; immunotherapy; ipilimumab; lichen planus; lichenoid inflammation; nivolumab; PD 1; pembrolizumab

Indexed keywords

IPILIMUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; STEROID;

ACANTHOSIS; ARTICLE; CLINICAL ARTICLE; DISEASE SEVERITY; ERYTHEMA; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERKERATOSIS; IMMUNOMODULATION; INFLAMMATION; LICHEN PLANUS; LICHENOID ERUPTION; MACULOPAPULAR RASH; MELANOMA; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; SKIN BIOPSY; ANTAGONISTS AND INHIBITORS; BIOPSY; CHEMICALLY INDUCED; CUTANEOUS DRUG ADMINISTRATION; DRUG EFFECTS; DRUG ERUPTIONS; LICHENOID ERUPTIONS; METABOLISM; NEOPLASMS; ORAL DRUG ADMINISTRATION; PATHOLOGY; PROSPECTIVE STUDY; SKIN; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; DRUG ERUPTIONS; HUMANS; LICHENOID ERUPTIONS; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; PROSPECTIVE STUDIES; SKIN; STEROIDS; TREATMENT OUTCOME;

EID: 85008440908     PISSN: 01931091     EISSN: 15330311     Source Type: Journal    
DOI: 10.1097/DAD.0000000000000587     Document Type: Article

References (15)

1. Harshman LC, Choueiri TK, Drake C. Subverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancer. Cancer J. 2014; 20:272-280
2. Wolchok JD, Hodi FS, Weber JS, et al. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci. 2013;1291:1-13
3. Mamalis A, Garcha M, Jagdeo J. Targeting the PD-1 pathway: a promising future for the treatment of melanoma. Arch Dermatol Res. 2014; 306:511-519
4. Hamid O, Robert C, Daud A, et al. Safety and tumour responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369: 134-144
5. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined Nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015; 373:23-34
6. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521-2532
7. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320-330
8. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity and immune correlated of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366: 2443-2454
9. Postow MA, Chesney J, Pavlick AC, et al. Niovlumab and ipilimumab versus ipililumab in untreated melanoma. N Engl J Med. 2015;372: 2006-2017
10. Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomized dose-comparison cohort of a phase 1 trial. Lancet. 2014;384:1109-1117
11. Hwang SJE, Carlos G, Wakade D, et al. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort. JAAD. 2016;74:455-461.e1
12. Carlos G, Anforth R, Chou S, et al. A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab. Melanoma Res. 2015;25:265-268
13. Joseph RW, Goedjen B, Gordon M, et al. Lichenoid dermatitis in three patients with metastatic melanoma treated with anti-PD-1 therapy. Cancer Immunol Res. 2015;3:18-22
14. Yong AA, Tey HL. Paraneoplastic pemphigus. Australas J Dermatol. 2015;54:241-250
15. Fernansez-Figueras MT, Puig L, Cannata P, et al. Grover disease: a reappraisal of histological diagnostic criteria in 120 cases. Am J Dermatopathol. 2010;23:541-549.